Prepaids and Other Current Assets (Notes)

12 Months Ended

Dec. 31, 2019

Prepaid Expense and Other Assets, Current [Abstract]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consist of the following (in thousands):



	December 31,
	2019		2018
Deposits	$	1,375	$	1,087
Other prepaid expenses and receivables	13,778		12,476
Receivables from Pfizer related to HIS business acquisition⁽¹⁾	—		20,137
Deferred costs	3,332		1,951
Prepaid insurance and property taxes	5,450		2,666
VAT/GST receivable	4,422		5,072
Deferred tax charge	1,266		1,180
Other	4,358		1,548
	$	33,981	$	46,117

___________________________________

⁽¹⁾ We reclassified the December 31, 2018 related-party receivable due from Pfizer to prepaid expenses and other current assets for current year presentation purposes. During the years 2018 and 2017, Pfizer was a related party to us as we issued 3.2 million shares of our common stock as partial consideration for the 2017 acquisition of HIS. As of December 31, 2018, Pfizer had sold all of its shares of our common stock. During 2018, in connection with the sale of the 2.5 million of the shares Pfizer held, we incurred a one-time fee payable to Pfizer in the amount of $8.0 million included in restructuring, strategic transaction and integration expense in our consolidated statement of operations.

Related-party revenue for goods manufactured for Pfizer under our Manufacturing and Supply Agreements with Pfizer (see Note 16, Collaborative and Other Arrangements) was $78.2 million and $72.4 million during the years 2018 and 2017, respectively, and the cost of product manufactured by Pfizer for us under those agreements was $81.0 million and $70.2 million during the years 2018 and 2017, respectively.